SCHEMBL5679771

SCHEMBL5679771

Cc1nn(CC(C)NC(=O)OC(C)(C)C)c2cc(Cl)c(F)cc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 9/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
ALOX12 P18054 1/20 0.38
EGFR P00533 1/20 0.37
KMO O15229 1/20 0.35
AAK1 Q2M2I8 3/20 0.35
MITF O75030 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PTGER1 P34995 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5679765 1.00 SLC22A12 (0.38) SLC22A12MAPTHPGDALDH1A1KDM4E
SCHEMBL5677709 0.92 AAK1 (0.36) SLC22A12KMOAAK1LMNAPTGDR2
SCHEMBL5677704 0.92 AAK1 (0.36) SLC22A12KMOAAK1LMNAPTGDR2
SCHEMBL5678047 0.79 GLS (0.43) MAPTHPGDALDH1A1KDM4EGAA
SCHEMBL5679666 0.79 DYRK1A (0.46) SLC22A12HPGDALDH1A1KDM4EHSD17B10
SCHEMBL5679657 0.79 DYRK1A (0.46) SLC22A12HPGDALDH1A1KDM4EHSD17B10
SCHEMBL8904901 0.75 HTR2C (0.56) MAPTHPGDALDH1A1KDM4EGAA
SCHEMBL905951 0.74 HTR2A (0.49) SLC22A12
SCHEMBL5678084 0.73 BRD4 (0.37) SLC22A12MAPTALDH1A1AAK1LMNA
SCHEMBL5678090 0.73 BRD4 (0.37) SLC22A12MAPTALDH1A1AAK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1129078-B1 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RES LTD (GB) 2006-03-15 EP disclosed
US-6552062-B1 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity VERNALIS RESEARCH LIMITED (GB) 2003-04-22 US disclosed